Adding a Second Drug for Febrile Children Treated With Acetaminophen
Primary Purpose
Fever
Status
Unknown status
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
Ibuprofen, acetaminophen
Sponsored by
About this trial
This is an interventional treatment trial for Fever
Eligibility Criteria
Inclusion Criteria:
- Age: 6 mo- 4 years
- Rectal temperature > 38.5
- Received 10-15 mg/kg of acetaminophen or 5-10 mg/kg of ibuprofen 1.5 - 3.5 hours before admission to the
Exclusion Criteria:
- Received more than 75 mg acetaminophen in the last 24 hours
- Unable to take oral medications
- Hypersensitivity to acetaminophen or ibuprofen
- Varicella
- Renal failure
- Liver disease
- Rectal temperature can't be measured (due to anatomical or medical problem)
- Received both Ibuprofen and acetaminophen in the last 6 hours
- Informed consent could not be granted
Sites / Locations
- Pediatric Emergency Medicine Service, Assaf Harofeh Medical CenterRecruiting
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT00389272
First Posted
October 17, 2006
Last Updated
October 30, 2007
Sponsor
Assaf-Harofeh Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT00389272
Brief Title
Adding a Second Drug for Febrile Children Treated With Acetaminophen
Official Title
Adding a Second Drug for Febrile Children Treated With Acetaminophen
Study Type
Interventional
2. Study Status
Record Verification Date
October 2006
Overall Recruitment Status
Unknown status
Study Start Date
September 2005 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
December 2008 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
Assaf-Harofeh Medical Center
4. Oversight
5. Study Description
Brief Summary
Fever is one of the most common symptoms in pediatrics and one of the most common reasons for visits in pediatricians' office and pediatric emergency departments. Many parents consider fever to be the most terrifying symptom.
Acetaminophen and ibuprofen are both effective and safe treatments for febrile children. In order to achieve better temperature control and to avoid toxicity it has been suggested to treat febrile children with alternating doses of acetaminophen and ibuprofen. Surveys in the USA and Spain found that this practice is very common. However, The safety and efficacy of such practice was never described.
Hypothesis:
Children who are still febrile after being treated with acetaminophen or ibuprofen will have greater temperature decrement if treated with another drug (acetaminophen for those treated with ibuprofen and ibuprofen for those treated with acetaminophen) than if treated with placebo.
Detailed Description
Methods:
Design: randomized double blind placebo controlled study. Setting: The ED and pediatric ward of a large University affiliated Hospital
Participants:
Inclusion criteria:
Age: 6 mo- 4 years
Rectal temperature > 38.5
Received 10-15 mg/kg of acetaminophen or 5-10 mg/kg of ibuprofen 1.5 - 3.5 hours before admission to the ED.
Exclusion criteria:
Received more than 75 mg acetaminophen in the last 24 hours
Unable to take oral medications
Hypersensitivity to acetaminophen or ibuprofen
Varicella
Renal failure
Liver disease
Rectal temperature can't be measured (due to anatomical or medical problem)
Received both Ibuprofen and acetaminophen in the last 6 hours
Informed consent could not be granted
Intervention:
Patients will be recruited in the ED and pediatric ward at Assaf Harofeh Medical Center. Legal guardians of eligible patients will be approached for consent. After obtaining informed consent a detailed history regarding the way fever was managed during the current illness will be collected (appendix 1). Patients will be randomized in a ratio of 2:1 (by a computer generated list of random numbers) into one of two groups. Group A will be treated with oral suspension of ibuprofen 10mg/kg (if the patient received acetaminophen at home) or oral suspension of acetaminophen 15 mg/kg (if treated previously with ibuprofen). The second group will be treated with the same amount of oral placebo suspension. The parents and the physician will be blinded to the treatment given. Body departure will be recoded at base line and at 15, 30, 60, 90, 120, 180 minutes after the drug administration. Blood sample for serum concentrations of acetaminophen or/and ibuprofen will be taken at the time of routine blood sampling according to the attending physician decision. Serum concentrations will not be measured if the attending physician decides that blood tests are not indicated.
Primary outcome:
· Maximal change in temperature during the 3-hour period after enrollment.
Secondary endpoints:
Proportion of patients with a drop of at least 1°C and 2°C in mean temperature at the end of the study (3 hours).
Decrement in fever at each time point, and the area under the temperature (versus time) curve for each group, calculated using the trapezoidal method. Continuous outcomes
Proportion of patients with temperature < 38 at the end of the study (3 hours).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fever
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
40 (Anticipated)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Ibuprofen, acetaminophen
10. Eligibility
Sex
All
Minimum Age & Unit of Time
6 Months
Maximum Age & Unit of Time
4 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age: 6 mo- 4 years
Rectal temperature > 38.5
Received 10-15 mg/kg of acetaminophen or 5-10 mg/kg of ibuprofen 1.5 - 3.5 hours before admission to the
Exclusion Criteria:
Received more than 75 mg acetaminophen in the last 24 hours
Unable to take oral medications
Hypersensitivity to acetaminophen or ibuprofen
Varicella
Renal failure
Liver disease
Rectal temperature can't be measured (due to anatomical or medical problem)
Received both Ibuprofen and acetaminophen in the last 6 hours
Informed consent could not be granted
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Eran Kozer, MD
Phone
972 8 9779916
Email
erank@asaf.health.gov.il
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Eran Kozer
Organizational Affiliation
Assaf-Harofeh Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Pediatric Emergency Medicine Service, Assaf Harofeh Medical Center
City
Zerifin
ZIP/Postal Code
70300
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eran Kozer, MD
12. IPD Sharing Statement
Learn more about this trial
Adding a Second Drug for Febrile Children Treated With Acetaminophen
We'll reach out to this number within 24 hrs